High cost
BPC-157 Frequently Asked Questions (Research Use Only) This FAQ provides structured, research-focused information about BPC-157, a synthetic peptide supplied as a lyophilized powder for controlled laboratory environments
In SURMOUNT-1 , a 72-week Phase 3 double-blind trial in 2,539 adults with obesity (or overweight with a complication) but without diabetes, once-weekly tirzepatide produced mean weight changes of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% with placebo, with 5057% of participants on the higher doses losing at least 20% of body weight
It means your body has adapted to the current dose and may need another increase
Adjust frequency based on your skin's response.Warnings:Patch Test: Prior to initial use, conduct a patch test on a small area of skin to check for any adverse reactions or sensitivities
Combine with moderate exercise for optimal results